CPIT is a randomised control trial (RCT) examining the effectiveness of financial incentives to help pregnant women stop smoking. To find out if financial incentives encourage pregnant smokers to attend the NHS stop smoking cessation services and/or to quit smoking during pregnancy the study will offer one group of women financial incentives as well as standard care and the other group standard care alone. The primary outcome will be validated abstinence towards the end of pregnancy.
Those pregnant smokers randomly placed in the incentive group could receive financial payments totaling £400:
£50 for attending a first face to face appointment with an NHS Smokefree Pregnancy adviser and setting a quit date.
£50 for being smokefree 4 weeks after quit date.
£100 validated for being smokefree 12 weeks after quit date.
£200 for being smokefree towards the end of pregnancy (at around 36 weeks gestation or when about 8 months pregnant).
These will be store vouchers which can be exchanged at many normal shop outlets.
1. What is likely therapeutic efficacy of financial incentives to encourage women to attend specialist cessation services, to set a quit date, to quit smoking and be abstinent towards the end of pregnancy?
2. Are incentives potentially cost-effective to help pregnant women to stop smoking?
3. Can incentives be introduced in a way that is feasible and acceptable to women and service providers and are there any unintended consequences?
4. What other factors need to be considered in designing a phase III RCT to follow on from this phase II trial?
Professor Linda Bauld
Institute for Social Marketing
University of Stirling
Smoking Cessation in Pregnancy
Incentives Trial (CPIT): a phase II RCT with economic evaluation (Presentation from June 2015)
THE CESSATION IN PREGNANCY INCENTIVES TRIAL (CPIT): STUDY PROTOCOL FOR A RANDOMIZED CONTROLLED TRIAL. (Released: July 2012)
Data will be collected at the following time points:
Informed consent to join trial:
At first face to face appointment and setting of quit date:
smoking cessation assessment
nicotine replacement therapy risk factor assessment
At 4 and 12 weeks post quit date:
self report and CO validated smoking status
At the end of pregnancy:
self reported and CO validated smoking status
biochemical validated smoking status
The study has 3 elements:
1. Randomised Controlled Trial (Phase II)
2. Health economics analysis
3. Interviews with pregnant smokers and members of staff
NHS Greater Glasgow & Clyde Health Board
Pregnant smokers living in the NHS Greater Glasgow & Clyde Board area.